David Williams
Concepts (529)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Enzyme Inhibitors | 5 | 2023 | 371 | 0.760 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 2 | 2023 | 14 | 0.600 |
Why?
| | Hypophosphatasia | 1 | 2018 | 8 | 0.580 |
Why?
| | Genetic Engineering | 1 | 2018 | 24 | 0.580 |
Why?
| | Alkaline Phosphatase | 1 | 2018 | 92 | 0.560 |
Why?
| | Disease Models, Animal | 5 | 2019 | 1517 | 0.560 |
Why?
| | Phenylenediamines | 1 | 2018 | 7 | 0.550 |
Why?
| | Cerebrovascular Circulation | 3 | 2016 | 132 | 0.520 |
Why?
| | Retroviridae Infections | 2 | 2013 | 2 | 0.490 |
Why?
| | Proto-Oncogene Proteins c-met | 5 | 2010 | 23 | 0.490 |
Why?
| | Personnel, Hospital | 2 | 2006 | 20 | 0.480 |
Why?
| | Tinnitus | 2 | 2017 | 64 | 0.470 |
Why?
| | Transcranial Magnetic Stimulation | 2 | 2017 | 72 | 0.470 |
Why?
| | Obesity | 7 | 2026 | 1204 | 0.460 |
Why?
| | Aminopyridines | 3 | 2010 | 19 | 0.460 |
Why?
| | Suction | 2 | 2013 | 22 | 0.430 |
Why?
| | Female | 49 | 2026 | 28782 | 0.420 |
Why?
| | Methamphetamine | 5 | 2014 | 190 | 0.420 |
Why?
| | Amines | 2 | 2014 | 38 | 0.420 |
Why?
| | Macaca mulatta | 2 | 2013 | 94 | 0.410 |
Why?
| | Humans | 62 | 2026 | 53230 | 0.400 |
Why?
| | Xenotropic murine leukemia virus-related virus | 1 | 2012 | 1 | 0.390 |
Why?
| | Wounds and Injuries | 2 | 2006 | 301 | 0.380 |
Why?
| | Antibodies, Monoclonal | 5 | 2014 | 477 | 0.380 |
Why?
| | Male | 44 | 2026 | 27435 | 0.370 |
Why?
| | Heart Rate | 5 | 2019 | 314 | 0.360 |
Why?
| | Structure-Activity Relationship | 11 | 2023 | 396 | 0.360 |
Why?
| | Rural Health Services | 2 | 2013 | 179 | 0.360 |
Why?
| | Caregivers | 3 | 2019 | 247 | 0.350 |
Why?
| | Protein Kinase Inhibitors | 3 | 2010 | 233 | 0.340 |
Why?
| | Intermittent Positive-Pressure Ventilation | 1 | 2011 | 19 | 0.340 |
Why?
| | Infant, Very Low Birth Weight | 1 | 2011 | 58 | 0.330 |
Why?
| | Depressive Disorder | 2 | 2010 | 336 | 0.330 |
Why?
| | Cost-Benefit Analysis | 2 | 2015 | 274 | 0.330 |
Why?
| | United States Department of Veterans Affairs | 3 | 2021 | 295 | 0.320 |
Why?
| | Antineoplastic Agents | 5 | 2010 | 1232 | 0.320 |
Why?
| | Intubation, Intratracheal | 1 | 2011 | 116 | 0.310 |
Why?
| | Animals | 29 | 2021 | 13526 | 0.310 |
Why?
| | Telemedicine | 3 | 2013 | 512 | 0.310 |
Why?
| | Respiration, Artificial | 2 | 2016 | 293 | 0.300 |
Why?
| | Breast Feeding | 2 | 2022 | 203 | 0.300 |
Why?
| | Maternal Nutritional Physiological Phenomena | 2 | 2020 | 64 | 0.300 |
Why?
| | Infant, Newborn | 10 | 2026 | 2913 | 0.290 |
Why?
| | Dietary Supplements | 3 | 2018 | 479 | 0.280 |
Why?
| | Time Factors | 10 | 2020 | 2991 | 0.280 |
Why?
| | Blood Pressure | 4 | 2016 | 518 | 0.270 |
Why?
| | Insulin Resistance | 2 | 2020 | 282 | 0.270 |
Why?
| | Gait Disorders, Neurologic | 2 | 2018 | 38 | 0.270 |
Why?
| | Leptin | 2 | 2022 | 151 | 0.260 |
Why?
| | Dietary Proteins | 2 | 2020 | 255 | 0.250 |
Why?
| | Pregnancy | 12 | 2026 | 2608 | 0.250 |
Why?
| | Brain | 5 | 2021 | 1350 | 0.250 |
Why?
| | Parkinson Disease | 2 | 2018 | 156 | 0.240 |
Why?
| | Accidents, Occupational | 1 | 2006 | 20 | 0.240 |
Why?
| | Adipogenesis | 1 | 2026 | 54 | 0.240 |
Why?
| | Infant, Premature | 5 | 2016 | 331 | 0.230 |
Why?
| | Adiposity | 2 | 2024 | 147 | 0.220 |
Why?
| | Occupational Diseases | 1 | 2006 | 82 | 0.220 |
Why?
| | Cerebral Hemorrhage | 2 | 2016 | 102 | 0.220 |
Why?
| | Cross-Over Studies | 7 | 2017 | 241 | 0.210 |
Why?
| | Veterans | 2 | 2021 | 580 | 0.210 |
Why?
| | Infant, Premature, Diseases | 2 | 2016 | 97 | 0.200 |
Why?
| | Rats, Sprague-Dawley | 12 | 2014 | 1544 | 0.200 |
Why?
| | Internship and Residency | 2 | 2019 | 439 | 0.200 |
Why?
| | Insulin | 3 | 2022 | 493 | 0.200 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2026 | 214 | 0.200 |
Why?
| | Depression | 3 | 2014 | 621 | 0.200 |
Why?
| | Ethers | 1 | 2023 | 7 | 0.200 |
Why?
| | Adult | 18 | 2026 | 14534 | 0.200 |
Why?
| | Pyrroles | 3 | 2008 | 73 | 0.200 |
Why?
| | Executive Function | 2 | 2021 | 78 | 0.190 |
Why?
| | Sertraline | 2 | 2014 | 48 | 0.190 |
Why?
| | Body Mass Index | 5 | 2026 | 717 | 0.190 |
Why?
| | Stress Disorders, Post-Traumatic | 2 | 2019 | 411 | 0.190 |
Why?
| | Students, Medical | 2 | 2017 | 157 | 0.180 |
Why?
| | Mitochondria | 1 | 2026 | 446 | 0.180 |
Why?
| | Maternal-Fetal Exchange | 2 | 2020 | 48 | 0.180 |
Why?
| | Liver Failure, Acute | 1 | 2022 | 57 | 0.180 |
Why?
| | Pedunculopontine Tegmental Nucleus | 2 | 2012 | 24 | 0.180 |
Why?
| | HeLa Cells | 2 | 2023 | 243 | 0.180 |
Why?
| | End Stage Liver Disease | 1 | 2022 | 52 | 0.170 |
Why?
| | Body Composition | 2 | 2020 | 355 | 0.170 |
Why?
| | Energy Metabolism | 2 | 2021 | 324 | 0.170 |
Why?
| | Phencyclidine | 2 | 2011 | 32 | 0.170 |
Why?
| | Evoked Potentials | 1 | 2021 | 67 | 0.170 |
Why?
| | Myocardium | 2 | 2021 | 471 | 0.170 |
Why?
| | Myoglobin | 1 | 2021 | 25 | 0.170 |
Why?
| | Middle Aged | 12 | 2019 | 13419 | 0.170 |
Why?
| | Olivary Nucleus | 2 | 2011 | 6 | 0.170 |
Why?
| | Purkinje Cells | 2 | 2011 | 15 | 0.170 |
Why?
| | Mice | 13 | 2021 | 5982 | 0.170 |
Why?
| | Cocaine-Related Disorders | 2 | 2014 | 206 | 0.170 |
Why?
| | Infant Food | 1 | 2020 | 28 | 0.160 |
Why?
| | Growth | 1 | 2020 | 40 | 0.160 |
Why?
| | Neurons | 3 | 2012 | 394 | 0.160 |
Why?
| | Rats | 12 | 2014 | 3162 | 0.160 |
Why?
| | Bottle Feeding | 1 | 2020 | 34 | 0.160 |
Why?
| | Spumavirus | 1 | 2020 | 1 | 0.160 |
Why?
| | Body Temperature Regulation | 1 | 2020 | 29 | 0.160 |
Why?
| | Microsomes, Liver | 3 | 2018 | 183 | 0.160 |
Why?
| | Acetaminophen | 2 | 2022 | 277 | 0.160 |
Why?
| | Blood Glucose | 2 | 2020 | 490 | 0.160 |
Why?
| | Brain Concussion | 1 | 2021 | 111 | 0.160 |
Why?
| | Cell Differentiation | 2 | 2026 | 681 | 0.150 |
Why?
| | Genome, Viral | 1 | 2020 | 78 | 0.150 |
Why?
| | Concept Formation | 1 | 2019 | 13 | 0.150 |
Why?
| | Temperature | 1 | 2020 | 165 | 0.150 |
Why?
| | Eating | 1 | 2020 | 159 | 0.150 |
Why?
| | Hepatic Veno-Occlusive Disease | 1 | 2019 | 11 | 0.150 |
Why?
| | Energy Intake | 1 | 2020 | 186 | 0.150 |
Why?
| | Phenotype | 2 | 2021 | 803 | 0.150 |
Why?
| | Case-Control Studies | 4 | 2019 | 1212 | 0.150 |
Why?
| | Athletic Injuries | 1 | 2021 | 193 | 0.150 |
Why?
| | Diastole | 2 | 2016 | 66 | 0.150 |
Why?
| | Middle Cerebral Artery | 2 | 2016 | 34 | 0.150 |
Why?
| | Diabetes, Gestational | 1 | 2019 | 52 | 0.150 |
Why?
| | Patient Care Team | 3 | 2013 | 278 | 0.150 |
Why?
| | Virus Replication | 1 | 2020 | 149 | 0.150 |
Why?
| | Freezing Reaction, Cataleptic | 1 | 2018 | 5 | 0.150 |
Why?
| | Feedback | 1 | 2019 | 53 | 0.140 |
Why?
| | Colorectal Surgery | 1 | 2018 | 16 | 0.140 |
Why?
| | Crystallography, X-Ray | 5 | 2010 | 155 | 0.140 |
Why?
| | Point Mutation | 1 | 2018 | 67 | 0.140 |
Why?
| | Sheep | 1 | 2018 | 99 | 0.140 |
Why?
| | Pyridones | 2 | 2009 | 38 | 0.140 |
Why?
| | Cannabidiol | 1 | 2019 | 44 | 0.140 |
Why?
| | Receptors, Growth Factor | 2 | 2008 | 7 | 0.140 |
Why?
| | Cell Line, Tumor | 7 | 2017 | 1470 | 0.140 |
Why?
| | Arkansas | 6 | 2019 | 2068 | 0.140 |
Why?
| | Treatment Outcome | 7 | 2017 | 5595 | 0.140 |
Why?
| | Certification | 1 | 2018 | 52 | 0.140 |
Why?
| | Burnout, Professional | 1 | 2019 | 58 | 0.140 |
Why?
| | Military Personnel | 2 | 2019 | 173 | 0.140 |
Why?
| | Bone Development | 1 | 2018 | 68 | 0.140 |
Why?
| | Child | 8 | 2024 | 7379 | 0.140 |
Why?
| | Ethanol | 2 | 2011 | 338 | 0.140 |
Why?
| | Blood Flow Velocity | 3 | 2016 | 99 | 0.140 |
Why?
| | Mental Health Services | 1 | 2021 | 233 | 0.140 |
Why?
| | Foot | 1 | 2018 | 41 | 0.140 |
Why?
| | Walking | 1 | 2018 | 106 | 0.130 |
Why?
| | Action Potentials | 3 | 2012 | 116 | 0.130 |
Why?
| | Cells, Cultured | 3 | 2026 | 1569 | 0.130 |
Why?
| | Proto-Oncogene Proteins | 2 | 2008 | 150 | 0.130 |
Why?
| | Psychiatry | 2 | 2017 | 104 | 0.130 |
Why?
| | United States | 7 | 2021 | 5409 | 0.130 |
Why?
| | Cognition | 1 | 2020 | 346 | 0.130 |
Why?
| | Parathyroid Hormone-Related Protein | 1 | 2017 | 23 | 0.130 |
Why?
| | Cellular Microenvironment | 1 | 2017 | 30 | 0.130 |
Why?
| | Platelet Activation | 1 | 2017 | 48 | 0.130 |
Why?
| | Electroacupuncture | 1 | 2016 | 2 | 0.130 |
Why?
| | Risk Factors | 6 | 2019 | 4017 | 0.130 |
Why?
| | Epinephrine | 1 | 2017 | 92 | 0.130 |
Why?
| | Pilot Projects | 3 | 2017 | 726 | 0.130 |
Why?
| | Pain | 2 | 2016 | 351 | 0.120 |
Why?
| | Combat Disorders | 1 | 2016 | 37 | 0.120 |
Why?
| | Blood Specimen Collection | 1 | 2016 | 34 | 0.120 |
Why?
| | Substance-Related Disorders | 2 | 2014 | 630 | 0.120 |
Why?
| | Attention | 1 | 2017 | 169 | 0.120 |
Why?
| | Perception | 1 | 2017 | 124 | 0.120 |
Why?
| | Citrus paradisi | 2 | 2008 | 10 | 0.120 |
Why?
| | Food-Drug Interactions | 2 | 2008 | 14 | 0.120 |
Why?
| | Serotonin | 1 | 2017 | 144 | 0.120 |
Why?
| | Cell Membrane | 1 | 2017 | 233 | 0.120 |
Why?
| | Neonatal Screening | 1 | 2016 | 49 | 0.120 |
Why?
| | Temporal Lobe | 2 | 2017 | 70 | 0.120 |
Why?
| | Career Choice | 1 | 2017 | 116 | 0.120 |
Why?
| | Itraconazole | 2 | 2008 | 37 | 0.120 |
Why?
| | Cerebral Ventricles | 1 | 2016 | 27 | 0.120 |
Why?
| | Melatonin | 1 | 2015 | 18 | 0.120 |
Why?
| | Physicians | 1 | 2019 | 242 | 0.120 |
Why?
| | Arterial Pressure | 1 | 2016 | 44 | 0.120 |
Why?
| | Antibodies, Viral | 2 | 2013 | 109 | 0.120 |
Why?
| | Quality of Life | 2 | 2019 | 902 | 0.120 |
Why?
| | Muscle, Skeletal | 1 | 2021 | 815 | 0.110 |
Why?
| | Bone Neoplasms | 1 | 2017 | 188 | 0.110 |
Why?
| | Blood Platelets | 1 | 2017 | 247 | 0.110 |
Why?
| | Cholinergic Agonists | 2 | 2011 | 10 | 0.110 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2010 | 228 | 0.110 |
Why?
| | Quality-Adjusted Life Years | 2 | 2015 | 67 | 0.110 |
Why?
| | Excitatory Amino Acid Agonists | 2 | 2011 | 15 | 0.110 |
Why?
| | Signal Transduction | 2 | 2022 | 1748 | 0.110 |
Why?
| | Amphetamine | 1 | 2014 | 36 | 0.110 |
Why?
| | Osteoclasts | 1 | 2017 | 428 | 0.100 |
Why?
| | Cyclohexanecarboxylic Acids | 1 | 2014 | 18 | 0.100 |
Why?
| | Autistic Disorder | 1 | 2015 | 126 | 0.100 |
Why?
| | Massage | 1 | 2014 | 6 | 0.100 |
Why?
| | Drinking | 2 | 2020 | 42 | 0.100 |
Why?
| | Severity of Illness Index | 4 | 2022 | 1049 | 0.100 |
Why?
| | Behavior Therapy | 1 | 2015 | 185 | 0.100 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2014 | 61 | 0.100 |
Why?
| | Equipment Failure Analysis | 1 | 2013 | 43 | 0.100 |
Why?
| | Simian foamy virus | 1 | 2013 | 1 | 0.100 |
Why?
| | Simian Acquired Immunodeficiency Syndrome | 1 | 2013 | 3 | 0.100 |
Why?
| | Antifungal Agents | 2 | 2008 | 350 | 0.100 |
Why?
| | Smoking | 1 | 2017 | 526 | 0.100 |
Why?
| | Aged | 6 | 2021 | 10429 | 0.100 |
Why?
| | Double-Blind Method | 4 | 2017 | 729 | 0.100 |
Why?
| | Binding Sites | 2 | 2014 | 373 | 0.100 |
Why?
| | Biophysical Phenomena | 1 | 2012 | 15 | 0.100 |
Why?
| | Drug Contamination | 1 | 2012 | 4 | 0.100 |
Why?
| | Nebulizers and Vaporizers | 1 | 2013 | 57 | 0.100 |
Why?
| | Bacillus | 1 | 2012 | 5 | 0.100 |
Why?
| | Albuterol | 1 | 2013 | 54 | 0.100 |
Why?
| | Models, Biological | 3 | 2019 | 737 | 0.100 |
Why?
| | Kangaroo-Mother Care Method | 1 | 2013 | 10 | 0.100 |
Why?
| | Saliva | 1 | 2013 | 56 | 0.100 |
Why?
| | Child, Preschool | 4 | 2024 | 4162 | 0.100 |
Why?
| | Cardiotonic Agents | 1 | 2013 | 70 | 0.100 |
Why?
| | Bronchodilator Agents | 1 | 2013 | 73 | 0.090 |
Why?
| | Coculture Techniques | 1 | 2012 | 146 | 0.090 |
Why?
| | Hydrocortisone | 1 | 2013 | 113 | 0.090 |
Why?
| | Drug Overdose | 1 | 2014 | 170 | 0.090 |
Why?
| | Hypotension | 1 | 2013 | 62 | 0.090 |
Why?
| | Dopamine | 1 | 2013 | 167 | 0.090 |
Why?
| | DNA, Viral | 1 | 2012 | 136 | 0.090 |
Why?
| | Primary Health Care | 3 | 2013 | 404 | 0.090 |
Why?
| | Registries | 1 | 2015 | 652 | 0.090 |
Why?
| | Anthropometry | 2 | 2024 | 101 | 0.090 |
Why?
| | Calcium Channels, N-Type | 1 | 2011 | 2 | 0.090 |
Why?
| | Intralaminar Thalamic Nuclei | 1 | 2011 | 6 | 0.090 |
Why?
| | Sequence Analysis, DNA | 1 | 2012 | 216 | 0.090 |
Why?
| | Functional Laterality | 1 | 2012 | 92 | 0.090 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2019 | 1367 | 0.090 |
Why?
| | Fetal Death | 1 | 2011 | 22 | 0.090 |
Why?
| | Polymerase Chain Reaction | 1 | 2012 | 452 | 0.090 |
Why?
| | Blotting, Western | 1 | 2012 | 587 | 0.090 |
Why?
| | Stem Cell Transplantation | 1 | 2012 | 191 | 0.090 |
Why?
| | Patch-Clamp Techniques | 4 | 2012 | 105 | 0.090 |
Why?
| | Sleep, REM | 1 | 2011 | 43 | 0.090 |
Why?
| | Pons | 1 | 2011 | 33 | 0.090 |
Why?
| | Pain Management | 1 | 2013 | 185 | 0.090 |
Why?
| | Brain Waves | 1 | 2011 | 19 | 0.090 |
Why?
| | Echoencephalography | 1 | 2011 | 8 | 0.090 |
Why?
| | Nerve Fibers | 1 | 2011 | 12 | 0.090 |
Why?
| | Electrocardiography | 1 | 2012 | 273 | 0.080 |
Why?
| | Neurogenesis | 1 | 2011 | 29 | 0.080 |
Why?
| | Central Nervous System Depressants | 1 | 2011 | 77 | 0.080 |
Why?
| | Longitudinal Studies | 3 | 2021 | 774 | 0.080 |
Why?
| | Stress, Psychological | 1 | 2013 | 282 | 0.080 |
Why?
| | Carbon Dioxide | 1 | 2011 | 97 | 0.080 |
Why?
| | Social Environment | 1 | 2011 | 82 | 0.080 |
Why?
| | Professional Role | 1 | 2011 | 85 | 0.080 |
Why?
| | Cerebellum | 1 | 2011 | 121 | 0.080 |
Why?
| | Atrial Fibrillation | 1 | 2012 | 197 | 0.080 |
Why?
| | Synapses | 1 | 2010 | 71 | 0.080 |
Why?
| | Administration, Oral | 4 | 2018 | 456 | 0.080 |
Why?
| | Linear Models | 3 | 2016 | 287 | 0.080 |
Why?
| | Teaching | 1 | 2011 | 111 | 0.080 |
Why?
| | Chronic Disease | 1 | 2012 | 580 | 0.080 |
Why?
| | Parents | 1 | 2013 | 341 | 0.080 |
Why?
| | Data Collection | 1 | 2011 | 288 | 0.080 |
Why?
| | Cross-Sectional Studies | 3 | 2021 | 1723 | 0.080 |
Why?
| | Dihydropyridines | 1 | 2009 | 7 | 0.080 |
Why?
| | Health Care Costs | 1 | 2010 | 178 | 0.070 |
Why?
| | Drug Design | 1 | 2010 | 121 | 0.070 |
Why?
| | Learning | 1 | 2011 | 156 | 0.070 |
Why?
| | Gestational Age | 3 | 2019 | 394 | 0.070 |
Why?
| | Body Weight | 2 | 2021 | 524 | 0.070 |
Why?
| | Cooperative Behavior | 1 | 2010 | 233 | 0.070 |
Why?
| | Phosphotransferases | 1 | 2008 | 18 | 0.070 |
Why?
| | Magnetic Resonance Imaging | 3 | 2021 | 1583 | 0.070 |
Why?
| | Liver | 3 | 2019 | 1150 | 0.070 |
Why?
| | Diet, High-Fat | 2 | 2021 | 243 | 0.070 |
Why?
| | Electroencephalography | 1 | 2010 | 305 | 0.070 |
Why?
| | Young Adult | 5 | 2017 | 4511 | 0.070 |
Why?
| | Mice, Inbred Strains | 2 | 2019 | 163 | 0.070 |
Why?
| | Urea | 1 | 2008 | 80 | 0.070 |
Why?
| | Breast Neoplasms | 1 | 2017 | 1222 | 0.070 |
Why?
| | Triazines | 1 | 2008 | 25 | 0.070 |
Why?
| | Beverages | 2 | 2008 | 58 | 0.070 |
Why?
| | Logistic Models | 2 | 2012 | 947 | 0.070 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2008 | 52 | 0.070 |
Why?
| | Stomach Neoplasms | 2 | 2008 | 207 | 0.070 |
Why?
| | Adolescent | 5 | 2021 | 6907 | 0.070 |
Why?
| | Central Nervous System Stimulants | 1 | 2009 | 201 | 0.060 |
Why?
| | Swimming | 1 | 2006 | 20 | 0.060 |
Why?
| | Monitoring, Physiologic | 2 | 2019 | 122 | 0.060 |
Why?
| | Bicycling | 1 | 2006 | 29 | 0.060 |
Why?
| | Chromatography, High Pressure Liquid | 2 | 2018 | 333 | 0.060 |
Why?
| | Running | 1 | 2006 | 23 | 0.060 |
Why?
| | Glioma | 1 | 2007 | 83 | 0.060 |
Why?
| | Motor Activity | 3 | 2014 | 227 | 0.060 |
Why?
| | Fetus | 3 | 2014 | 191 | 0.060 |
Why?
| | Proportional Hazards Models | 1 | 2007 | 445 | 0.060 |
Why?
| | Cell Respiration | 1 | 2026 | 49 | 0.060 |
Why?
| | Prospective Studies | 3 | 2019 | 2411 | 0.060 |
Why?
| | Receptors, Vasopressin | 1 | 2005 | 23 | 0.060 |
Why?
| | Multiple Myeloma | 2 | 2012 | 3082 | 0.060 |
Why?
| | Cell Survival | 3 | 2017 | 600 | 0.060 |
Why?
| | Alkyl and Aryl Transferases | 1 | 2005 | 4 | 0.060 |
Why?
| | Dogs | 2 | 2020 | 186 | 0.060 |
Why?
| | Ambulatory Care | 2 | 2021 | 239 | 0.060 |
Why?
| | Poliomyelitis | 1 | 2005 | 5 | 0.060 |
Why?
| | Ambulatory Care Facilities | 2 | 2021 | 121 | 0.060 |
Why?
| | Mice, Inbred C57BL | 2 | 2021 | 1925 | 0.060 |
Why?
| | Benzodiazepines | 1 | 2005 | 72 | 0.060 |
Why?
| | Spheroids, Cellular | 1 | 2005 | 27 | 0.060 |
Why?
| | Quinolines | 1 | 2005 | 44 | 0.060 |
Why?
| | Kinetics | 2 | 2020 | 607 | 0.060 |
Why?
| | Area Under Curve | 3 | 2014 | 185 | 0.060 |
Why?
| | Cyclin-Dependent Kinases | 1 | 2004 | 26 | 0.050 |
Why?
| | beta-Cyclodextrins | 1 | 2004 | 15 | 0.050 |
Why?
| | Predictive Value of Tests | 2 | 2017 | 934 | 0.050 |
Why?
| | Thiazoles | 1 | 2004 | 52 | 0.050 |
Why?
| | Protein Binding | 3 | 2014 | 670 | 0.050 |
Why?
| | Brain Neoplasms | 1 | 2007 | 319 | 0.050 |
Why?
| | Placebos | 2 | 2014 | 80 | 0.050 |
Why?
| | Louisiana | 2 | 2019 | 41 | 0.050 |
Why?
| | Insurance Benefits | 1 | 2003 | 7 | 0.050 |
Why?
| | Insurance, Psychiatric | 1 | 2003 | 5 | 0.050 |
Why?
| | Cell Proliferation | 4 | 2008 | 1031 | 0.050 |
Why?
| | Odds Ratio | 2 | 2016 | 567 | 0.050 |
Why?
| | Palmitates | 1 | 2022 | 28 | 0.050 |
Why?
| | Health Services | 1 | 2003 | 71 | 0.050 |
Why?
| | Community Mental Health Services | 1 | 2003 | 48 | 0.050 |
Why?
| | Drug Evaluation, Preclinical | 2 | 2017 | 142 | 0.050 |
Why?
| | L-Lactate Dehydrogenase | 1 | 2022 | 57 | 0.050 |
Why?
| | Clinical Competence | 2 | 2018 | 406 | 0.050 |
Why?
| | Sex Factors | 2 | 2019 | 747 | 0.050 |
Why?
| | Reproducibility of Results | 2 | 2019 | 1219 | 0.040 |
Why?
| | Statistics, Nonparametric | 2 | 2012 | 198 | 0.040 |
Why?
| | Physical Therapy Modalities | 1 | 2021 | 40 | 0.040 |
Why?
| | Glucose Tolerance Test | 1 | 2021 | 61 | 0.040 |
Why?
| | Psychiatric Status Rating Scales | 2 | 2013 | 325 | 0.040 |
Why?
| | Carbachol | 2 | 2011 | 26 | 0.040 |
Why?
| | Medically Uninsured | 1 | 2021 | 52 | 0.040 |
Why?
| | Postural Balance | 1 | 2021 | 59 | 0.040 |
Why?
| | Sodium Channel Blockers | 2 | 2011 | 14 | 0.040 |
Why?
| | Athletes | 1 | 2021 | 104 | 0.040 |
Why?
| | Weight Gain | 1 | 2022 | 245 | 0.040 |
Why?
| | Membrane Potentials | 2 | 2011 | 100 | 0.040 |
Why?
| | Analysis of Variance | 2 | 2013 | 547 | 0.040 |
Why?
| | Veterans Health | 1 | 2021 | 61 | 0.040 |
Why?
| | Diet, Fat-Restricted | 1 | 2020 | 13 | 0.040 |
Why?
| | Attitude | 1 | 2021 | 72 | 0.040 |
Why?
| | Mice, Obese | 1 | 2020 | 22 | 0.040 |
Why?
| | Animals, Newborn | 2 | 2012 | 357 | 0.040 |
Why?
| | Reaction Time | 1 | 2021 | 207 | 0.040 |
Why?
| | Body Fat Distribution | 1 | 2020 | 10 | 0.040 |
Why?
| | Cytopathogenic Effect, Viral | 1 | 2020 | 5 | 0.040 |
Why?
| | Macaca | 1 | 2020 | 9 | 0.040 |
Why?
| | Fatty Acids | 1 | 2021 | 154 | 0.040 |
Why?
| | Lipid Metabolism | 1 | 2021 | 189 | 0.040 |
Why?
| | Absorptiometry, Photon | 1 | 2020 | 160 | 0.040 |
Why?
| | Adipose Tissue, Brown | 1 | 2020 | 45 | 0.040 |
Why?
| | Alcoholism | 1 | 2003 | 242 | 0.040 |
Why?
| | Oxidation-Reduction | 1 | 2021 | 333 | 0.040 |
Why?
| | Memory | 1 | 2020 | 97 | 0.040 |
Why?
| | Neuroimaging | 1 | 2020 | 95 | 0.040 |
Why?
| | Sex Characteristics | 1 | 2021 | 204 | 0.040 |
Why?
| | Patient Compliance | 2 | 2014 | 232 | 0.040 |
Why?
| | Family Relations | 1 | 2019 | 23 | 0.040 |
Why?
| | Proteomics | 1 | 2022 | 336 | 0.040 |
Why?
| | Cohort Studies | 2 | 2016 | 1557 | 0.040 |
Why?
| | Exercise | 1 | 2024 | 561 | 0.040 |
Why?
| | Phylogeny | 1 | 2020 | 231 | 0.040 |
Why?
| | Language | 1 | 2020 | 147 | 0.040 |
Why?
| | Drug Synergism | 1 | 2019 | 147 | 0.040 |
Why?
| | Mothers | 1 | 2021 | 269 | 0.040 |
Why?
| | Students | 1 | 2021 | 249 | 0.040 |
Why?
| | Neuropsychological Tests | 1 | 2020 | 345 | 0.040 |
Why?
| | Specialty Boards | 1 | 2018 | 23 | 0.040 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2020 | 180 | 0.040 |
Why?
| | Interpersonal Relations | 1 | 2019 | 116 | 0.040 |
Why?
| | Retrospective Studies | 2 | 2012 | 6819 | 0.040 |
Why?
| | Mice, Knockout | 1 | 2021 | 910 | 0.040 |
Why?
| | Animals, Outbred Strains | 1 | 2017 | 12 | 0.030 |
Why?
| | Social Support | 1 | 2019 | 272 | 0.030 |
Why?
| | Serotonin 5-HT2 Receptor Antagonists | 1 | 2017 | 9 | 0.030 |
Why?
| | Transglutaminases | 1 | 2017 | 14 | 0.030 |
Why?
| | Parietal Lobe | 1 | 2017 | 26 | 0.030 |
Why?
| | Cell Line | 1 | 2020 | 1016 | 0.030 |
Why?
| | Toxicity Tests | 1 | 2017 | 57 | 0.030 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2017 | 68 | 0.030 |
Why?
| | Adaptation, Psychological | 1 | 2019 | 233 | 0.030 |
Why?
| | Organ Size | 1 | 2017 | 226 | 0.030 |
Why?
| | Emergency Service, Hospital | 1 | 2021 | 530 | 0.030 |
Why?
| | Platelet Aggregation | 1 | 2017 | 77 | 0.030 |
Why?
| | Polysaccharides | 1 | 2017 | 57 | 0.030 |
Why?
| | Educational Measurement | 1 | 2018 | 202 | 0.030 |
Why?
| | Medicine | 1 | 2017 | 51 | 0.030 |
Why?
| | Mice, Nude | 2 | 2009 | 232 | 0.030 |
Why?
| | Plant Extracts | 1 | 2019 | 200 | 0.030 |
Why?
| | Prognosis | 1 | 2022 | 2118 | 0.030 |
Why?
| | Prefrontal Cortex | 1 | 2017 | 85 | 0.030 |
Why?
| | Education, Medical, Graduate | 1 | 2019 | 219 | 0.030 |
Why?
| | Protein Transport | 1 | 2017 | 168 | 0.030 |
Why?
| | Psychomotor Performance | 1 | 2017 | 126 | 0.030 |
Why?
| | Feeding Behavior | 1 | 2018 | 195 | 0.030 |
Why?
| | Accidental Falls | 1 | 2018 | 107 | 0.030 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2017 | 108 | 0.030 |
Why?
| | Inhibitory Concentration 50 | 2 | 2008 | 75 | 0.030 |
Why?
| | Cannabis | 1 | 2019 | 155 | 0.030 |
Why?
| | Models, Molecular | 2 | 2009 | 352 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2017 | 237 | 0.030 |
Why?
| | Umbilical Arteries | 1 | 2016 | 16 | 0.030 |
Why?
| | Pharmaceutical Solutions | 2 | 2008 | 9 | 0.030 |
Why?
| | Autonomic Nervous System | 1 | 2016 | 60 | 0.030 |
Why?
| | Ultrasonography, Doppler, Transcranial | 1 | 2016 | 24 | 0.030 |
Why?
| | Apgar Score | 1 | 2016 | 26 | 0.030 |
Why?
| | Molecular Structure | 2 | 2008 | 320 | 0.030 |
Why?
| | Infant, Extremely Premature | 1 | 2016 | 33 | 0.030 |
Why?
| | Tandem Mass Spectrometry | 1 | 2017 | 254 | 0.030 |
Why?
| | Prevalence | 1 | 2019 | 1034 | 0.030 |
Why?
| | Up-Regulation | 1 | 2017 | 456 | 0.030 |
Why?
| | Calcium | 1 | 2017 | 373 | 0.030 |
Why?
| | Echocardiography | 1 | 2018 | 409 | 0.030 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2017 | 213 | 0.030 |
Why?
| | Cost of Illness | 1 | 2015 | 121 | 0.030 |
Why?
| | Binding Sites, Antibody | 1 | 2014 | 14 | 0.030 |
Why?
| | Locomotion | 1 | 2014 | 79 | 0.030 |
Why?
| | GABA Agonists | 1 | 2014 | 13 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2016 | 598 | 0.030 |
Why?
| | Diagnosis, Dual (Psychiatry) | 1 | 2014 | 42 | 0.030 |
Why?
| | Half-Life | 1 | 2014 | 86 | 0.030 |
Why?
| | Amphetamine-Related Disorders | 1 | 2014 | 93 | 0.030 |
Why?
| | Particle Size | 1 | 2013 | 76 | 0.030 |
Why?
| | CD4 Lymphocyte Count | 1 | 2013 | 33 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2018 | 1112 | 0.030 |
Why?
| | MicroRNAs | 1 | 2017 | 397 | 0.020 |
Why?
| | Administration, Inhalation | 1 | 2013 | 108 | 0.020 |
Why?
| | T-Lymphocyte Subsets | 1 | 2013 | 39 | 0.020 |
Why?
| | Aerosols | 1 | 2013 | 74 | 0.020 |
Why?
| | Biophysics | 1 | 2012 | 12 | 0.020 |
Why?
| | Nasal Cavity | 1 | 2013 | 7 | 0.020 |
Why?
| | Viral Load | 1 | 2013 | 83 | 0.020 |
Why?
| | Infant, Extremely Low Birth Weight | 1 | 2013 | 29 | 0.020 |
Why?
| | Plasma | 1 | 2013 | 47 | 0.020 |
Why?
| | Ion Channel Gating | 1 | 2012 | 30 | 0.020 |
Why?
| | Theophylline | 1 | 2012 | 18 | 0.020 |
Why?
| | Touch | 1 | 2013 | 23 | 0.020 |
Why?
| | Infant Behavior | 1 | 2013 | 18 | 0.020 |
Why?
| | Medically Underserved Area | 1 | 2013 | 46 | 0.020 |
Why?
| | Neurotransmitter Agents | 1 | 2012 | 32 | 0.020 |
Why?
| | Electric Stimulation | 1 | 2012 | 103 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2014 | 405 | 0.020 |
Why?
| | Remission Induction | 1 | 2013 | 221 | 0.020 |
Why?
| | Medication Adherence | 1 | 2014 | 136 | 0.020 |
Why?
| | Equipment Design | 1 | 2013 | 290 | 0.020 |
Why?
| | Systole | 1 | 2012 | 71 | 0.020 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2014 | 150 | 0.020 |
Why?
| | Ion Channels | 1 | 2012 | 70 | 0.020 |
Why?
| | Caffeine | 1 | 2012 | 64 | 0.020 |
Why?
| | Sleep | 1 | 2014 | 195 | 0.020 |
Why?
| | Heart Atria | 1 | 2012 | 64 | 0.020 |
Why?
| | Recurrence | 1 | 2014 | 694 | 0.020 |
Why?
| | Psychotherapy | 1 | 2013 | 117 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2014 | 640 | 0.020 |
Why?
| | omega-Agatoxin IVA | 1 | 2011 | 1 | 0.020 |
Why?
| | Infant | 1 | 2020 | 3805 | 0.020 |
Why?
| | Antidepressive Agents | 1 | 2013 | 177 | 0.020 |
Why?
| | Survival Analysis | 1 | 2013 | 659 | 0.020 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2012 | 107 | 0.020 |
Why?
| | Calcium Channel Blockers | 1 | 2011 | 57 | 0.020 |
Why?
| | Oscillometry | 1 | 2011 | 7 | 0.020 |
Why?
| | Sodium Channels | 1 | 2011 | 10 | 0.020 |
Why?
| | Secondary Prevention | 1 | 2011 | 85 | 0.020 |
Why?
| | Cystic Fibrosis | 1 | 2013 | 155 | 0.020 |
Why?
| | Principal Component Analysis | 1 | 2011 | 53 | 0.020 |
Why?
| | Acculturation | 1 | 2011 | 24 | 0.020 |
Why?
| | Social Identification | 1 | 2011 | 20 | 0.020 |
Why?
| | Microscopy, Confocal | 1 | 2011 | 75 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2011 | 109 | 0.020 |
Why?
| | Femoral Artery | 1 | 2011 | 106 | 0.020 |
Why?
| | Clinical Clerkship | 1 | 2011 | 29 | 0.020 |
Why?
| | Ultrasonography | 1 | 2012 | 426 | 0.020 |
Why?
| | Transplantation, Autologous | 1 | 2012 | 488 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2011 | 89 | 0.020 |
Why?
| | Vesicular Glutamate Transport Protein 2 | 1 | 2010 | 5 | 0.020 |
Why?
| | Cerebellar Cortex | 1 | 2010 | 5 | 0.020 |
Why?
| | Tetrodotoxin | 1 | 2010 | 8 | 0.020 |
Why?
| | N-Methylaspartate | 1 | 2010 | 14 | 0.020 |
Why?
| | Theta Rhythm | 1 | 2010 | 7 | 0.020 |
Why?
| | Electrophysiological Phenomena | 1 | 2010 | 19 | 0.020 |
Why?
| | Schools, Medical | 1 | 2011 | 68 | 0.020 |
Why?
| | Muscarinic Agonists | 1 | 2010 | 10 | 0.020 |
Why?
| | Potassium Channel Blockers | 1 | 2010 | 15 | 0.020 |
Why?
| | Kainic Acid | 1 | 2010 | 24 | 0.020 |
Why?
| | Potassium Channels | 1 | 2010 | 32 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2011 | 487 | 0.020 |
Why?
| | Disease Progression | 1 | 2013 | 880 | 0.020 |
Why?
| | Cell Count | 1 | 2010 | 141 | 0.020 |
Why?
| | Kidney Diseases | 1 | 2012 | 230 | 0.020 |
Why?
| | Pregnancy Outcome | 1 | 2011 | 231 | 0.020 |
Why?
| | Stereotyped Behavior | 1 | 2009 | 16 | 0.020 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2011 | 235 | 0.020 |
Why?
| | Age Factors | 1 | 2013 | 1136 | 0.020 |
Why?
| | Dextroamphetamine | 1 | 2009 | 36 | 0.020 |
Why?
| | Incidence | 1 | 2012 | 1085 | 0.020 |
Why?
| | Fetal Development | 1 | 2009 | 50 | 0.020 |
Why?
| | Blood Proteins | 1 | 2009 | 84 | 0.020 |
Why?
| | Solubility | 1 | 2009 | 83 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2009 | 211 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2008 | 38 | 0.020 |
Why?
| | fms-Like Tyrosine Kinase 3 | 1 | 2008 | 20 | 0.020 |
Why?
| | Ether-A-Go-Go Potassium Channels | 1 | 2008 | 5 | 0.020 |
Why?
| | Caco-2 Cells | 1 | 2008 | 31 | 0.020 |
Why?
| | Kidney | 1 | 2012 | 715 | 0.020 |
Why?
| | Risk Assessment | 1 | 2012 | 1368 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2008 | 310 | 0.020 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2008 | 78 | 0.020 |
Why?
| | Protein Conformation | 1 | 2008 | 174 | 0.020 |
Why?
| | Hypertension | 1 | 2012 | 554 | 0.020 |
Why?
| | Glutathione Transferase | 1 | 2008 | 174 | 0.020 |
Why?
| | Exercise Tolerance | 1 | 2006 | 43 | 0.020 |
Why?
| | Physical Endurance | 1 | 2006 | 35 | 0.020 |
Why?
| | Hepatocytes | 1 | 2008 | 188 | 0.020 |
Why?
| | Computer Simulation | 1 | 2007 | 290 | 0.020 |
Why?
| | Respiration | 1 | 2006 | 94 | 0.020 |
Why?
| | Benzazepines | 1 | 2005 | 20 | 0.010 |
Why?
| | Molecular Weight | 1 | 2005 | 77 | 0.010 |
Why?
| | Oxygen Consumption | 1 | 2006 | 201 | 0.010 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2006 | 250 | 0.010 |
Why?
| | Farnesyltranstransferase | 1 | 2005 | 4 | 0.010 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2005 | 136 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2007 | 630 | 0.010 |
Why?
| | Tumor Cells, Cultured | 1 | 2005 | 441 | 0.010 |
Why?
| | Cyclodextrins | 1 | 2004 | 16 | 0.010 |
Why?
| | Biological Availability | 1 | 2004 | 107 | 0.010 |
Why?
| | Leukemia | 1 | 2004 | 67 | 0.010 |
Why?
| | Neoplasms, Experimental | 1 | 2004 | 112 | 0.010 |
Why?
| | Gatekeeping | 1 | 2003 | 9 | 0.010 |
Why?
| | Cost Control | 1 | 2003 | 13 | 0.010 |
Why?
| | Tennessee | 1 | 2003 | 37 | 0.010 |
Why?
| | Cost Sharing | 1 | 2003 | 17 | 0.010 |
Why?
| | Georgia | 1 | 2003 | 42 | 0.010 |
Why?
| | Alabama | 1 | 2003 | 67 | 0.010 |
Why?
| | Mississippi | 1 | 2003 | 90 | 0.010 |
Why?
| | Health Policy | 1 | 2003 | 165 | 0.010 |
Why?
|
|
Williams's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|